Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial

Nature Medicine · Published 2026-07-09 · DOI 10.1038/s41591-026-04525-0

Free full text

Authors (21)

G. Paul, H. Bjartmarz, A. Kirkeby, J. Nelander, R. Smith, S. Kayhanian, A. Evans, B. Harry, E. Cutting, S. Fazal, N. P. Lao-Kaim, T. van Vliet, S. Ullén, I. Grubor, Oskar Hansson, P. Piccini, O. Lindvall, A. Björklund, H. Widner, M. Parmar, Roger A Barker

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Paul, G., Bjartmarz, H., Kirkeby, A., et al. (2026). Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial. Nature Medicine. https://doi.org/10.1038/s41591-026-04525-0

Related articles